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Abstract Germline mutations in the breast cancer susceptibil-
ity genes, BRCA1 and BRCA2, are thought to account for a
large portion of familial breast cancer. The increased risk of
breast cancer in women carrying such mutations suggests that
these proteins play a critical role in the growth regulation of
mammary epithelial cells. Another protein, Stat5a, is known to
be essential for growth and terminal di¡erentiation of breast
epithelial cells. Here we show that Stat5a forms a complex
with both BRCA1 and BRCA2 in breast epithelial cells upon
stimulation with prolactin. In addition, we show that the activity
of Stat5a on the L-casein promoter is modulated by both
BRCA1 and BRCA2. This interaction may be important during
the expansion and terminal di¡erentiation of breast epithelial
cells, as happens during pregnancy and lactation.
( 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The breast cancer susceptibility genes BRCA1 and BRCA2
were identi¢ed by studies of families with inherited suscepti-
bility to breast cancer. Mutations in these genes predispose to
breast cancer as well as to other types of cancers such as
prostate and ovarian cancer. Their normal protein products
share many functional properties and both are involved in the
fundamental cellular processes of maintaining genomic integ-
rity, transcriptional regulation and embryonic cell prolifera-
tion (reviewed in [1]). It is not clear why mutations in these
ubiquitously expressed genes, which participate in universal
pathways, lead speci¢cally to breast and ovarian cancer, but
studies in mice have shown that expression of BRCA1 and
BRCA2 is associated with the growth and di¡erentiation of
breast epithelial cells, especially during pregnancy and lacta-
tion. Both proteins are markedly up-regulated in the mam-
mary gland early in pregnancy, during proliferation of breast
epithelial cells as well as during di¡erentiation to mature,
milk-producing alveoli [2,3]. Increased knowledge about the
normal functions of BRCA1 and BRCA2 proteins in signal
transduction and growth regulation in breast cells may thus
shed light on the pathogenesis of hereditary breast cancer and
reveal how direct or indirect inactivation of BRCA genes
leads to breast tumorigenesis.
Stats (signal transducers and activators of transcription) are
a family of transcription factors that mediate the transcrip-
tional response to a diverse group of cytokines and growth
factors. Upon binding these ligands, the receptors phosphor-
ylate the Stats, which then dimerize, move to the nucleus and
induce the transcription of speci¢c genes [4]. Stat5a, also
known as mammary gland factor, is activated by many cyto-
kines and growth factors, including prolactin (PRL), growth
hormone, and epidermal growth factor, and mediates the
transcription of milk proteins such as L-casein, whey acidic
protein and oncostatin M (reviewed in [4,5]). Studies of
knockout mice have revealed that the STAT5a gene is neces-
sary for normal development of the mammary gland.
STAT5a3=3 mice are normal in size, weight and fertility,
but female mice fail to lactate after parturition and are unable
to nurse. The lobulo-alveolar units of the mammary tissue are
extremely underdeveloped and do not show a secretory phe-
notype, even after maximal stimulation of PRL secretion [6].
Stat5a is strongly activated towards the end of pregnancy,
persists in an activated state during pregnancy and lactation
and is rapidly inactivated after cessation of suckling [7,8].
Stat5a, BRCA1 and BRCA2 are all up-regulated in the
mammary gland during pregnancy and lactation and these
proteins all have an important role in the normal development
of breast epithelial cells. BRCA1 and BRCA2 are also known
to interact with each other [9]. We therefore asked whether
Stat5a interacted with BRCA1 and BRCA2 in breast epithe-
lial cells.
2. Materials and methods
2.1. Cells and tissue culture
COS-7 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
(Life Technologies) supplemented with 10% fetal calf serum, 100 U/ml
penicillin, and 100 Wg/ml streptomycin. T47D and MCF-7 cells were
cultured in RPMI medium supplemented with 10% fetal calf serum,
100 U/ml penicillin, 100 Wg/ml streptomycin and 10 Wg/ml insulin.
2.2. Antisera and reagents
The rat monoclonal antibody SC-3 was raised against the C-termi-
nal amino acids 3386^3400 of human BRCA2. Rabbit antiserum
against Stat5a was purchased from Santa Cruz and mouse monoclo-
nal antibody against BRCA1 (mAb1) was from Oncogene Research
Products. Monoclonal anti-HA (3F10) was purchased from Boehr-
inger Mannheim and monoclonal anti-£ag (M5) was from Sigma.
Peroxidase-conjugated pig anti-rabbit immunoglobulins and sheep
anti-mouse immunoglobulin were from Amersham. The rabbit anti-
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serum PDGFR-33 has been described previously [10]. Ovine PRL
(sheep luteotropic hormone) was purchased from Sigma.
2.3. Plasmids and cDNA transfections
The plasmids pMT-SMII and pMT-SMII/5P£ag-BRCA2 have been
previously described [11]. The plasmid pcDNA3L/5PHA-BRCA1 was
provided by Ralph Scully, Dana Farber Institute, Boston, MA, USA.
Stat5a cDNA (pXM-Stat5) [12] and L-casein promoter (pZZ1; 3344
to 31 L-casein promoter 5P pLucDSS) [13] were provided by Bernd
Groner, Institute for Biomedical Research, Georg-Spyer-Haus,
Frankfurt, Germany. pcDNA3-PDGF L-receptor was provided by
Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala,
Sweden. pCH110 encoding the L-galactosidase gene under the control
of the SV40 promoter was from Pharmacia Biotech. Transient trans-
fections were performed with Fugene-6 (Boehringer Mannheim) using
0.7 Wg of each cDNA and keeping the total amount of cDNA con-
stant using empty vector.
2.4. Cell lysis and immunoprecipitation
T47D cells and MCF-7 cells were starved for 24 h, and then stimu-
lated with 5 Wg/ml PRL (sheep luteotropic hormone) for di¡erent time
periods at 37‡C. After washing with phosphate-bu¡ered saline (PBS),
cells were solubilized in lysis bu¡er containing 1% Triton X-100, 1%
sodium deoxycholate, 10% glycerol, 20 mM Tris^HCl, pH 7.5, 150
mM NaCl, 2.5 mM EDTA, 1 mM phenylmethylsulfonyl £uoride, 1%
Trasylol, 100 WM NaVO3. The lysates were centrifuged and the super-
natants immunoprecipitated with speci¢c antibodies for 2 h at 4‡C,
followed by incubation with protein G-Sepharose 4 Fast Flow (Amer-
sham Pharmacia Biotech AB) for 30 min. Immunoprecipitates were
washed twice with lysis bu¡er, eluted from the Sepharose beads and
analyzed by SDS^gel electrophoresis in a gradient gel of 5^10% poly-
acrylamide. The samples were electrophoretically transferred to Im-
mun-Blot polyvinylidene di£uoride membrane (Bio-Rad) at 400 mA
for 3^4 h at 4‡C in 20% methanol, 0.2 M glycine, and 25 mM Tris^
HCl. Blots were blocked by incubation in PBS containing 5% dried
milk and 0.05% Tween 20 (Merck) for 1 h at room temperature before
probing with speci¢c antibodies. After incubation with di¡erent anti-
sera, the blots were washed three times in PBS containing 0.05%
Tween 20 and then incubated with the peroxidase-conjugated pig
anti-rabbit or sheep anti-mouse immunoglobulins (1:5000 and
1:1000 dilutions, respectively). After washing, bound antibodies
were visualized using the ECL Western blotting detection system.
2.5. Luciferase and L-galactosidase assays
COS-7 cells or T47D cells were left untreated or stimulated with
either 50 ng/ml PDGF-BB or 5 Wg/ml PRL for 8^16 h. Then L-galac-
tosidase and luciferase activities were determined on triplicate samples
using the L-galactosidase and luciferase assay systems (Promega) as
described by the manufacturer. Luciferase activities were corrected for
the L-galactosidase values obtained in each experiment.
3. Results
To test for potential interaction between BRCA1 and Stat-
5a, COS-7 cells were transfected with cDNAs encoding
STAT5a and HA-BRCA1, either alone or in combination
with each other. Forty-eight hours after transfection, the cells
were lysed to obtain cell extracts, which were incubated with
anti-HA mAb. The immunoprecipitates were separated by
SDS^PAGE and immunoblotted with antiserum against
Stat5a. As shown in Fig. 1A, Stat5a co-precipitated with
C
Fig. 1. Stat5a co-precipitates with BRCA1 and BRCA2 in transi-
ently transfected COS-7 cells. A: COS-7 cells were transiently trans-
fected with pcDNA3 alone, BRCA1-HA, Stat5a or a combination
of BRCA1-HA and Stat5a. After 48 h, the cells were lysed and im-
munoprecipitated with anti-HA, followed by immunoblotting with
anti-Stat5a (upper panel) and BRCA1 (middle panel). In parallel,
expression levels of Stat5a were assessed by immunoblotting 10% of
the cell lysate with anti-Stat5a (bottom panel). B: The experiments
described in A were repeated using pcDNA3 alone, Flag-BRCA2,
STAT5a or a combination of Flag-BRCA2 and Stat5a. The cell ly-
sates were then immunoprecipitated (IP) with anti-Flag, followed by
SDS^PAGE and immunoblotting (IB) with anti-Stat5a (upper panel)
and anti-BRCA2 (middle panel). In addition, expression levels of
Stat5a were assessed by immunoblotting 10% of the cell lysate with
anti-Stat5a (bottom panel).
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HA-BRCA1 in cells overexpressing these two proteins. In
addition, 10% of the cell lysate was immunoblotted with
anti-Stat5a to con¢rm equal expression of the transfected pro-
tein (Fig. 1A, bottom panel). To investigate whether Stat5a
also co-precipitated with BRCA2, COS-7 cells were trans-
fected with plasmids encoding STAT5a and £ag-BRCA2, ei-
ther alone or in combination with each other. As shown in
Fig. 1B, Stat5a co-precipitated with £ag-BRCA2 in cells over-
expressing these proteins. As before, 10% of the cell lysate was
immunoblotted with anti-Stat5a (Fig. 1B, bottom panel) to
con¢rm equal expression of the transfected protein.
We then asked if Stat5a could interact with BRCA1 and
BRCA2 under endogenous conditions. Also, we wanted to
examine if such an interaction was induced by tyrosine phos-
phorylation of Stat5a. For this purpose, we used the breast
cancer cell lines MCF-7 and T47D, which have been shown to
express PRL receptors on the cell surface [14] as well as en-
dogenous Stat5a, BRCA1 and BRCA2 [15^17]. To examine
whether tyrosine-phosphorylated Stat5a was detected in these
cells upon short-term ligand stimulation, serum-starved T47D
cells were stimulated with 5 Wg/ml ovine PRL for 15 and 30
min at 37‡C. Stat5a was immunoprecipitated from the cell
lysates with speci¢c anti-Stat5a antiserum, followed by
SDS^PAGE and immunoblotting with anti-phosphotyrosine
antibody. As shown in Fig. 2, tyrosine-phosphorylated Stat5a
was detected upon stimulation with PRL for 15 min, in agree-
ment with previous studies [15]. Similar results were obtained
using MCF-7 cells (data not shown).
In order to estimate if Stat5a formed an endogenous com-
plex with BRCA1, MCF-7 cells were serum-starved and then
stimulated with 5 Wg/ml ovine PRL for 15 and 30 min at 37‡C.
BRCA1 was immunoprecipitated from the cell lysates with
anti-BRCA1 mAb. Precipitated proteins were analyzed by
SDS^PAGE, followed by immunoblotting with anti-BRCA1
(Fig. 3A, upper panel) or anti-Stat5a (Fig. 3A, middle panel),
showing that a BRCA1^Stat5a complex was indeed present in
the breast cells upon ligand stimulation. 10% of the cell lysates
were run in parallel and immunoblotted with anti-Stat5a to
con¢rm the expression of Stat5a in all lanes (Fig. 3A, bottom
panel). To examine the speci¢city of the reaction, cell lysates
from PRL-stimulated T47D cells were immunoprecipitated
with anti-BRCA1 mAb or anti-HA mAb, the latter was
used as a negative control. The precipitated proteins were
analyzed by SDS^PAGE, followed by immunoblotting with
Fig. 2. Tyrosine phosphorylation of Stat5a in response to PRL. Se-
rum-starved T47D cells were stimulated with 5 Wg/ml ovine PRL,
for 15 or 30 min at 37‡C. Cells were lysed and immunoprecipitated
with anti-Stat5a, followed by SDS^PAGE and immunoblotting with
anti-phosphotyrosine (upper panel), and anti-Stat5a (lower panel).
Fig. 3. Stat5a co-precipitates with BRCA1 in PRL-stimulated breast
cells. A: Serum-starved MCF-7 cells were stimulated with 5 Wg/ml
ovine PRL for 15 or 30 min at 37‡C. Cells were lysed and immuno-
precipitated (IP) with anti-BRCA1 mAb, followed by SDS^PAGE
and immunoblotting (IB) with anti-BRCA1 (upper panel) or anti-
Stat5a (middle panel). In parallel, expression levels of Stat5a were
assessed by immunoblotting 10% of the cell lysate with anti-Stat5a
(bottom panel). B: As in A, except that T47D cells were cultured in
RPMI medium supplemented with 10% fetal calf serum, 100 U/ml
penicillin, 100 Wg/ml streptomycin and 10 Wg/ml insulin. After serum
starvation for 24 h, the cells were stimulated with 5 Wg/ml ovine
PRL for 15 min and immunoprecipitated (IP) with anti-BRCA1
(lanes 1 and 2) or anti-HA (lane 3), followed by immunoblotting
with anti-Stat5a.
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anti-BRCA1 (Fig. 3B, upper panel) or anti-Stat5a (Fig. 3B,
middle panel). Endogenous Stat5a co-precipitated speci¢cally
with anti-BRCA1 antibodies in response to PRL, whereas
anti-HA mAb did not precipitate Stat5a. In addition, 10%
of the protein lysate was immunoblotted with Stat5a, to check
protein levels (Fig. 3B, bottom panel).
To determine whether endogenous Stat5a also forms a
physical complex with BRCA2 in breast cancer cells,
BRCA2 was immunoprecipitated with an anti-BRCA2 mAb
(Sc-3) from extracts of MCF-7 cells. As shown in Fig. 4,
middle panel, Stat5a indeed precipitated with BRCA2 after
15 min stimulation with PRL at 37‡C. The ¢lter was also
immunoblotted with anti-BRCA2 (Fig. 4, top panel) and
10% of the protein lysate was immunoblotted with Stat5a,
to check protein levels (Fig. 4, bottom panel). Both BRCA1
and BRCA2 thus appear to form a physical complex with
Stat5a in breast epithelial cells upon ligand stimulation.
Stat5a dimers bind the L-casein promoter on ligand stimu-
lation, increasing expression of the gene. To examine whether
the interaction between BRCA2 and Stat5a a¡ected the lat-
ter’s transcriptional activity, COS-7 cells were transfected with
the L-casein promoter driving a luciferase reporter (pZZ1),
together with di¡erent combinations of cDNAs encoding
STAT5a, PDGF L-receptor or BRCA2, using a plasmid encod-
ing a L-galactosidase reporter (CH-110) as a control for trans-
fection e⁄ciency. The total amount of transfected DNA was
kept constant using empty vector. As shown in Fig. 5A, stim-
ulation with PDGF-BB induced transcriptional activity of
exogenous Stat5a, in agreement with previous studies [18].
This induction was signi¢cantly decreased in cells overexpress-
ing BRCA2 protein (Fig. 5A, lane 6), although transfection
with BRCA2 alone had no e¡ect on expression of the reporter
(Fig. 5A, lane 4).
To investigate whether both BRCA1 and BRCA2 could
modulate the transcriptional activity of Stat5a in breast cell
lines, T47D cells were transiently transfected with the report-
ers used in the previous experiment together with di¡erent
combinations of cDNAs encoding STAT5a, the PDGF L-re-
ceptor, BRCA1 or BRCA2. As shown in Fig. 5B, the tran-
scriptional activity of Stat5a was markedly decreased in cells
overexpressing either BRCA1 or BRCA2. To investigate
whether this inhibition also a¡ected the Stat5a activity in-
duced by PRL treatment, T47D cells were transfected with
the L-casein and control reporters together with di¡erent com-
binations of cDNAs encoding STAT5a, BRCA1 or BRCA2.
The cells were either left untreated or stimulated with PRL for
16 h. The PRL-induced transcription of the L-casein reporter
was markedly decreased by co-transfection of either BRCA1
or BRCA2 (Fig. 5C). As shown in Figs. 1A and 1B (lanes 3
and 4), co-transfection of BRCA1 or BRCA2 had no e¡ect on
the level of ectopic Stat5a expressed in COS-7 cells, excluding
the possibility that the inhibition of Stat5a transcriptional
activity resulted from changes in the level of Stat5a. Neither
BRCA1 nor BRCA2 proteins had any toxic e¡ects when over-
expressed as judged by £ow cytometry (data not shown). The
transcriptional activity of Stat5a induced by both PRL and
PDGF thus appears to be inhibited by BRCA1 and BRCA2
in cells overexpressing these proteins.
4. Discussion
We have shown that the transcription factor Stat5a inter-
acts with BRCA1 and BRCA2 after stimulation with PRL.
Such stimulation induces tyrosine phosphorylation of Stat5a,
which is followed by dimerization and translocation into the
nucleus [15]. The interaction was also detected without ligand
stimulation, in COS-7 cells overexpressing these proteins,
however, the COS-7 cells were not serum-starved before lysis,
giving the possibility that cytokines in the medium induced
tyrosine phosphorylation of Stat5a.
The increased risk of breast cancer in women carrying
germline mutations in BRCA1 and BRCA2 suggests that these
proteins play a critical role in the growth regulation of mam-
mary epithelial cells, perhaps regulating signaling pathways
during pregnancy and lactation. The mammary gland devel-
ops at puberty and undergoes further changes during and
after each pregnancy. The initial rapid proliferation of the
breast epithelium is followed by di¡erentiation during the lat-
er stages of pregnancy. The development of the mammary
gland re£ects the precise interplay of multiple hormones
such as estrogens, growth hormones, insulin and corticoste-
roids which synergize with PRL in the development of the
fully functional mammary gland. Lactation is initiated as a
result of increasing PRL concentrations whereas glandular
involution is induced by decreasing concentrations of PRL
and postlactational apoptosis [8].
Most breast cancers originate in the terminal end ducts or
intralobular terminal ducts. These structures are most numer-
ous in nulliparous women and are lost on di¡erentiation dur-
ing pregnancy and lactation. An early age at ¢rst full-term
pregnancy and increased parity are both associated with
long-term reductions in the risk of breast cancer. After preg-
Fig. 4. Stat5a co-precipitates with BRCA2 in PRL-stimulated MCF-
7 cells. Serum-starved MCF-7 cells were stimulated with 5 Wg/ml
ovine PRL for 15 min at 37‡C. Cell lysates were immunoprecipi-
tated (IP) with anti-BRCA2 mAb (Sc-3), followed by SDS^PAGE
and immunoblotting (IB) with anti-BRCA2 (Sc-3) (upper panel) or
anti-Stat5a (middle panel). In parallel, 10% of the lysate was immu-
noblotted with anti-Stat5a (bottom panel) to con¢rm expression of
the protein in all lanes.
FEBS 26790 19-11-02
H. Vidarsson et al./FEBS Letters 532 (2002) 247^252250
nancy, the risk of breast cancer transiently increases, but it
subsequently remains lower for a period extending into the
postmenopausal years [19,20]. In carriers of germline muta-
tions in BRCA1 and BRCA2, however, pregnancy may in-
crease the risk of breast cancer, according to a study by Jern-
stro«m et al. [20].
BRCA1 and BRCA2 function as transcriptional co-regula-
tors through direct interaction with sequence-speci¢c tran-
scription factors and with components of the transcriptional
machinery. In addition, chromatin remodeling functions have
been attributed to both BRCA1 and BRCA2 (reviewed in [1]).
In our study, BRCA1 and BRCA2 proteins suppressed the
transcriptional activity of Stat5a on the L-casein promoter.
The mechanism by which BRCA1 and BRCA2 suppress
Stat5a activity remains to be elucidated. They do not appear
to decrease the level of the Stat5a protein (Fig. 1A,B, bottom
panel) or its DNA binding activity (results not shown), and
may instead modulate its capacity to a¡ect transcription. Oth-
er transcription factors are known to in£uence the activity of
Stat5. Thus, for example, the glucocorticoid receptor binds to
Stat5 and enhances its transcriptional activity, while proteins
such as PIAS and Socs inhibit its transcriptional activity
through di¡erent mechanisms [5]. It is not known whether
any of these proteins interact with BRCA1 or BRCA2.
BRCA1 has previously been found to act in concert with
Stat1 to activate transcription of interferon-Q target genes
and mediate growth inhibition by this cytokine. In that study,
BRCA1 interacted directly with Stat1 [21]. Similarly, Stat1
was recently found to be up-regulated by BRCA1, in a
BRCA1-inducible cell line [22]. Although Stat1 and Stat5
are structurally very similar, they seem to play di¡erent roles
in cells. Thus, Stat1 has been suggested to induce growth in-
hibition and apoptosis in breast cells, whereas Stat5 promotes
cellular proliferation and di¡erentiation [23].
PRL, the main activator of Stat5a in mammary cells, has
been shown to be one of the important growth factors that
promote proliferation of breast cancer cells. PRL induces
growth of mammary tumors in rodent models in vivo, and
the PRL receptor has both autocrine and paracrine activity in
breast cancer cells in vitro (reviewed in [24]). In addition,
higher plasma levels of PRL are associated with an increased
risk of breast cancer in postmenopausal women [25]. Recent
studies have indicated that PRL activates the cyclin D1 pro-
moter via the Jak-Stat pathway [26]. Cyclin D1, which is over-
expressed in many breast tumors, has been suggested to play a
crucial role in the development of breast cancer malignancy
[23]. Interestingly, cyclin D1 has recently also been shown to
be transcriptionally down-regulated by BRCA1 in BRCA1-
inducible cells [22]. The results of our study indicate that
BRCA1 and BRCA2 may help to limit the PRL-induced ac-
tivation of Stat5a during periods such as glandular involution,
when the activity of Stat5a is known to be down-regulated at
C
Fig. 5. Decreased transcriptional activity of Stat5a in cells overex-
pressing BRCA1 or BRCA2. A: COS-7 cells transfected with L-ca-
sein promoter luciferase construct (all columns), L-galactosidase
(pCH110, all columns), STAT5a cDNA (columns 1,3,5,6), PDGF
L-receptor (columns 4^6) or Flag-BRCA2 (columns 2^4, 6) were
stimulated with 100 ng/ml PDGF-BB for 8 h. The transcriptional
activity of Stat5a on the L-casein promoter was determined by lucif-
erase assay (Pharmingen) in triplicate samples using L-galactosidase
assays (Pharmingen) as a control. B: T47D cells transfected with
L-casein promoter luciferase construct, L-galactosidase (pCH110, all
columns), STAT5a (all columns), PDGF L-receptor (columns 2^4),
HA-BRCA1 (column 3), or Flag-BRCA2 (column 4) were stimulated
with 100 ng/ml PDGF-BB for 8 h. The transcriptional activity of
Stat5a on the L-casein promoter was determined by luciferase assay
as before. C: As in B, except that T47D cells were stimulated with
5 Wg/ml PRL (+, columns 2^4) for 16 h and transcriptional activity
of Stat5a determined by luciferase assay and L-casein promoter.
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the same time as the expression of BRCA1 and BRCA2 is
increased [3].
In conclusion, we have shown that both BRCA1 and
BRCA2 associate with Stat5a on ligand stimulation and mod-
ulate its transcriptional activity. This interaction may be im-
portant for the terminal di¡erentiation of breast epithelial
cells during pregnancy and lactation, and its failure may
play a role in the pathogenesis of breast cancer.
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